Evaluation The effect of Selenium on Reducing Kidney Damage Following Cisplatin intake

Evaluation The Effect of Selenium on Reducing Nephrotoxicity Due to Cisplatin Intake

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201116049407N1

Enrollment

Registered

2021-01-24

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In this study, patients admitted to the hematology ward selected by physician for cisplatin injection are studied. The primary type of disease can include testicular tumors, head and neck tumors, cervical cancer, lung cancer, and tumor germ germ.. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Intervention group: Patients admitted to the hematology ward who need to inject cisplatin, receive selenium at a dose of 40 micrograms daily for up to two days after cisplatin taking e

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Absence of kidney disease and any kidney failure Do not take other nephrotoxic drugs such as nephrotoxic antibiotics indications for taking cisplatin to the patient

Exclusion criteria

Exclusion criteria: starting nephrotoxic drug is for the patient during treatment Reducing of the patient to continue cooperation Acute and chronic renal failure

Design outcomes

Primary

Measure	Time frame
Urine level of KIM-1. Timepoint: At the beginning of treatment, and two days after the end of the treatment period. Method of measurement: The assay immunosorbent linked-enzyme (ELISA).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayye Dadbeh

Mashhad University of Medical Sciences

S.dadbeh80@gmail.com+98 51 3726 9021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026